Cancer has always posed a fierce challenge to modern medicine, especially when it comes to tumors that target blood cells and the lymphatic system, such as lymphoma. However, amidst this challenge, a new glimmer of hope called CAR T-Cell therapy emerges, so what is this therapy? How can modified immune cells become a lethal weapon against this invisible enemy?
Lymphoma is a type of cancer that is initiated inside the lymphocytes, which are part of the immune system that helps the body fight infection. There are two main types of lymphoma; Hodgkin lymphoma and lymphoma. Each one of them has different subtypes. Traditional treatment options include chemotherapy, radiation therapy, and stem cell transplantation. Nevertheless, for patients with advanced or treatment-resistant forms, finding innovative solutions becomes crucial.
One form of immunotherapy known as chimeric receptor T-cell therapy (CAR T-Cell) is currently being used increasingly to treat some patients with non-Hodgkin's lymphoma (NHL). However, to date, the use of this type of treatment is limited to patients who have already received several previous forms of treatment, but it is not yet clear whether the use of chimeric receptor T-cell therapy in the early stages of the disease course will be more effective in fighting cancer than the standard treatment of chemotherapy and stem cell transplantation.
New results from three large-scale clinical trials now indicate that, following initial chemotherapy, CAR T-cell therapy may be more effective than standard treatment; several researchers have noted the potential for using this therapy in the early stages of the disease course. All three studies included patients with aggressive non-Hodgkin's B-cell lymphoma, the most common type of this cancer, whose cancer returned early or worsened after their initial treatment.
Chimeric receptor T-cell therapy provides engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens on the surface of lymphoma cells. The treatment consists of several steps; first, T cells are collected from patients and genetically modified to produce these chimeric receptors. Then, the genetically modified T cells are cultured in the laboratory until their number reaches billions of cells, then they are re-injected into the patient's body.
Despite the promising results achieved by CAR T-Cell therapy in some types of treatment-resistant lymphoma, it has some potential side effects, some of which include:
- Cytokine Release Syndrome (CRS): This is an excessive inflammatory response that happens as a result of the activation of a large number of immune cells; its symptoms can range from fever and chills to low blood pressure and difficulty breathing.
- Neurotoxicity: CAR T-Cell treatment can affect the nervous system, leading to symptoms such as confusion, seizures, and difficulty in speaking or understanding.
- B-cell aplasia: Because CAR T-Cell targets a protein that is also present on some normal B cells, treatment may lead to a deficiency of these cells, increasing the risk of infection.
- Low blood count: A decrease in red blood cells, white blood cells, and platelets may occur.
Eventually, CAR T-Cell therapy represents a quantum leap in the field of lymphoma treatment, especially for patients who have not responded to traditional therapies. However, with these enormous possibilities come challenges and side effects that require careful management and continuous monitoring. Will this innovative approach continue to evolve into a standard and safer treatment for a larger number of lymphoma patients, thus opening new horizons in combating this complex disease?
References
cancer.gov
lymphoma-action.org.uk
lymphoma.org
pmc.ncbi.nlm.nih.gov
Cover image by Magnific